Q-omics provides the consensus-scored MED8 profile across patient tissues and cancer cell-line models. MED8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MED8 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MED8 protein abundance shows 26,418 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where MED8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED8 survival associations across molecular data types. MED8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED8 RNA expression–survival associations across cancer types. High MED8 expression shows unfavorable associations in ACC, LIHC, KICH, LGG, KIRP and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MED8 RNA expression.
This table summarizes MED8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MED8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED8 shows higher tumor expression in KIRC, HNSC, LIHC, LUAD, BLCA and STAD. The KIRC box plot shows higher MED8 RNA expression in tumor versus normal tissue (log2 FC = +0.588, t-test p < 0.001).
This table shows molecular features associated with MED8 in patient tissues and cancer cell lines. In patient samples, MED8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
